Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus
| Autor: | Alexandra Ward, Maribel Salas, Judith A. O'Brien |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Pharmacology
medicine.medical_specialty Combination therapy Cost effectiveness business.industry Cost-Benefit Analysis Administration Oral Type 2 Diabetes Mellitus General Medicine Type 2 diabetes medicine.disease Metformin Diabetes Mellitus Type 2 Weight loss Diabetes mellitus medicine Humans Hypoglycemic Agents Pharmacology (medical) medicine.symptom Intensive care medicine business Pioglitazone medicine.drug |
| Zdroj: | Expert Opinion on Pharmacotherapy. 6:601-608 |
| ISSN: | 1744-7666 1465-6566 |
| DOI: | 10.1517/14656566.6.4.601 |
| Popis: | Diabetes is a public health problem worldwide. Its treatment includes controlling hyperglycaemia, initially through changes in lifestyle such as diet, exercise and weight loss. UK Prospective Diabetes Study results showed that intensive treatment to achieve glycaemic control in patients with type 2 diabetes reduces the risk of diabetes-related complications. Typically, patients initially receive monotherapy with oral hypoglycaemic agents but usually progress to combination therapy or insulin. In the short term, the cost of achieving glycaemic control can be substantial, particularly when combination therapy is required. However, additional treatment costs of achieving recommended glycaemic control levels are predicted to be at least partially offset in the long term by the reduction of diabetes-related complications and their related management costs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|